VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Immune escape is a prerequisite for tumor development. To avoid the immune system, tumors develop different mechanisms, including T cell exhaustion, which is characterized by expression of immune inhibitory receptors, such as PD-1, CTLA-4, Tim-3, and a progressive loss of function. The recent development of therapies targeting PD-1 and CTLA-4 have raised great interest since they induced long-lasting objective responses in patients suffering from advanced metastatic tumors. However, the regulation of PD-1 expression, and thereby of exhaustion, is unclear. VEGF-A, a proangiogenic molecule produced by the tumors, plays a key role in the development of an immunosuppressive microenvironment. We report in the present work that VEGF-A produced in the tumor microenvironment enhances expression of PD-1 and other inhibitory checkpoints involved in CD8+ T cell exhaustion, which could be reverted by anti-angiogenic agents targeting VEGF-A–VEGFR. In view of these results, association of anti-angiogenic molecules with immunomodulators of inhibitory checkpoints may be of particular interest in VEGF-A-producing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have demonstrated that VEGF blockade can reverse T cell failure and enhance the therapeutic effect of ICI [59,60].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [59]
In the citing paper
“expression of co-inhibitory receptors, including PD-1 by CD8 + CTLs”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Voron et al., 2015
In the citing paper
“First, increased VEGF directly inhibits CTL trafficking, proliferation, and effector function22”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [22]
In the citing paper
“Secondly, VEGF could inhibit the maturation of DC, induce the exhaustion of T cells, promote the proliferation of Tregs, and increase the ratio of MDSCs [90–93].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“2015 Vol. 212 No. 2 139–148 www.jem.org/cgi/doi/10.1084/jem.20140559 139 Brief Definit ive Report One of the major processes involved in tumor appearance and growth is the capacity of tumor cells to develop escape mechanisms to the immune system (Schreiber et al., 2011).”
BackgroundInfluentialWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“The mechanisms involved in PD-1 expression and exhaustion of tumor-infiltrating T cells are poorly understood, even though a link to antigen persistence has been suggested (Wherry, 2011).”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · cited 1×
“In tumors or during chronic viral infections, PD-1 expression is maintained (Wherry et al., 2007).”
BackgroundTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 6×
“Cell surface-staining was performed on tumor-infiltrating cells using antiCD8 (53–6.7; eBioscience), anti–PD-1 (J43; eBioscience), anti–CTLA-4 (UC10-4B9; BioLegend), anti–Lag-3 (C9B7W; BioLegend), anti–Tim-3 (RMT3-23; BioLegend), anti–mouse VEGF-R2 (89B3A5; BioLegend), and anti–mouse VEGF-R1 (141522; R&D Systems).”
BackgroundInfluentialBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · cited 1×
“To determine whether VEGF-R1 or VEGF-R2 are involved in the T cells express these receptors the more they are dysfunctional (Blackburn et al., 2009).”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Cited by
Items 301–400 of 1,000
Albiges, L. K., Barthélémy, P., Gross‐Goupil, M., Négrier, S., Needle, M. N., & Escudier, B. J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.021 · Cited by 60
The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells
Cheng, H., Ma, K., Zhang, L., & Li, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.013 · Cited by 65
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 71
Immunotherapeutic approaches for hepatocellular carcinoma
Longo, V., Gnoni, A., Gardini, A. C., Pisconti, S., Licchetta, A., Scartozzi, M., Memeo, R., Palmieri, V. O., Aprile, G., Santini, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15406 · Cited by 59
“, on the other hand, showed that VEGF induces exhaustion in intratumoral CD8+ T cells by promoting the expression of PD-1 and other checkpoint molecules such us CTLA-4 and TIM-3 [25].”
BackgroundFerrarotto, R., de Sousa, L. G., Feng, L., Mott, F. E., Blumenschein, G. R., Altan, M., Bell, D., Bonini, F., Li, K., Marques-Piubelli, M. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02221 · Cited by 64
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
Mahmoud, F. A., Shields, B. D., Makhoul, I., Avaritt, N. L., Wong, H. K., Hutchins, L. F., Shalin, S. C., & Tackett, A. J. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323596 · Cited by 60
CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression
Mu, L., Yang, C., Gao, Q., Long, Y., Ge, H., DeLeon, G., Jin, L., Chang, Y. E., Sayour, E. J., Ji, J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01451 · Cited by 56
“This drug inhibits the formation of tumor blood vessels induced by vascular endothelial growth factor A (VEGF-A); increases T cell infiltrations (9, 10); reverses expression of inhibitory molecules associated with T cell exhaustion (11); and may directly mediate antitumor effect (12).”
BackgroundLee, J. J., & Chu, E. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.06.004 · Cited by 58
“Of note, the combination of PD-1 blockade with the inhibition of VEGF pathway induces a strong synergistic antitumor effect in the murine CT26 CRC model.(101)”
BackgroundGao, L., Yang, X., Cheng, Y., & Zhu, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01173 · Cited by 58
“Firstly, VEGF directly prevent mobilization, trafficking, development, proliferation, and effector function of CD8-positive cytotoxic T lymphocytes (CTLs) (Ohm and Carbone, 2001; Voron et al., 2015).”
BackgroundLaubli, H. P., Müller, P., D’Amico, L., Buchi, M., Kashyap, A. S., & Zippelius, A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2136-x · Cited by 56
Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
Veldman, J., Visser, L., van den Berg, A., & Diepstra, A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101931 · Cited by 56
“PD-1, CTLA-4, TIM3, LAG-3) on CD8+ T cells, inducing an exhausted phenotype [69,70].”
BackgroundVascular mimicry: changing the therapeutic paradigms in cancer
Maroufi, N. F., Taefehshokr, S., Rashidi, M., Taefehshokr, N., Khoshakhlagh, M., Isazadeh, A., Mokarizadeh, N., Baradaran, B., & Nouri, M. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05515-2 · Cited by 56
Nishida, N. (2021) · Cancers · doi:10.3390/cancers13153666 · Cited by 66
“Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that suppress tumor immunity and can be induced by VEGF [16].”
BackgroundNew Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma
Mossenta, M., Busato, D., Baboçi, L., Cintio, F. D., Toffoli, G., & Bo, M. D. (2019) · Cancers · doi:10.3390/cancers11081086 · Cited by 56
“Moreover, anti-VEGF agents could inhibit the expression of immune checkpoint inhibitors (ICIs) such as PD-L1, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) in infiltrating CD8+ T cells [34].”
BackgroundResistance of Lenvatinib in Hepatocellular Carcinoma
Xu, Q., Huang, D., Guo, J., & Zhao, J. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220428111327 · Cited by 61
The application and research progress of anti-angiogenesis therapy in tumor immunotherapy
Tu, J., Liang, H., Li, C., Huang, Y., Wang, Z., Chen, X., & Yuan, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1198972 · Cited by 56
“Increased VEGF directly inhibits the transport, proliferation and functions of cytotoxic T lymphocytes (CTLs) (69, 70).”
BackgroundBotta, C., Martino, M. T. D., Ciliberto, D., Cucè, M., Correale, P., Rossi, M., Tagliaferri, P., & Tassone, P. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.118 · Cited by 55
Strategies to overcome therapeutic resistance in renal cell carcinoma
Siska, P. J., Beckermann, K. E., Rathmell, W. K., & Haake, S. M. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.12.002 · Cited by 58
“[54], tumor-infiltrating Teff cells also express VEGFR1 and VEGFR2.”
BackgroundPD-1/PD-L1 axis importance and tumor microenvironment immune cells
Lotfinejad, P., Kazemi, T., Mokhtarzadeh, A., Shanehbandi, D., Jadidi‐Niaragh, F., Safaei, S., Asadi, M., & Baradaran, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118297 · Cited by 55
Lanitis, E., Kosti, P., Ronet, C., Cribioli, E., Rota, G., Spill, A., Reichenbach, P., Zoete, V., Laniti, D. D., Coukos, G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002151 · Cited by 55
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
Rowdo, F. P. M., Barón, A., Urrutia, M., & Mordoh, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00127 · Cited by 55
“They proposed that the release of VEGF-A by the tumor enhances the expression of inhibitory immune checkpoint molecules (PD-1, Tim-3, CTLA-4, and Lag-3) on activated CD8+ T cells in tumors (95).”
BackgroundVasilev, G., Ivanova, M. G., Ivanova‐Todorova, E., Tumangelova-Yuzeir, K. D., Krasimirova, E., Stoilov, R. M., & Kyurkchiev, D. S. (2019) · Rheumatology International · doi:10.1007/s00296-019-04296-7 · Cited by 51
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression
Cai, X., Wei, B., Li, L., Chen, X., Liu, W., Cui, J. T., Lin, Y., Sun, Y., Xu, Q., Guo, W., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106858 · Cited by 58
Li, J., Cong, L., Liu, J., Peng, L., Wang, J., Feng, A., Yue, J., Li, L., Wang, X., & Wang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.594125 · Cited by 52
The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Luo, F., Li, M., Ding, J., & Zheng, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635731 · Cited by 55
Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
Buqué, A., Bloy, N., Aranda, F., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Tartour, É., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149674 · Cited by 51
“Along similar lines, VEGFA-targeting mAbs such as the FDA-approved agent bevacizumab(50) prevent VEGFA-dependent T-cell exhaustion and stimulate the normalization of the tumor vasculature, which favors tumor infiltration by immune effector cells.(49,61)”
BackgroundIssafras, H., Fan, S., Tseng, C.-L., Cheng, Y., Lin, P.-H., Xiao, L., Huang, Y.-J., Tu, C., Hsiao, Y.-C., Li, M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257972 · Cited by 54
“The possible mechanisms of action include: (1) VEGF-A secreted by tumor cells in the tumor microenvironment induces the expression of PD-1 and other immune checkpoint inhibitory molecules on CD8 T-cells, which is related to the exhaustion of T-cells within tumors [26]; (2) Anti-angiogenic agents can normalize the bloo…”
BackgroundCurrent Trends in Mucosal Melanomas: An Overview
Santeufemia, D. A., Palmieri, G., Miolo, G., Colombino, M., Doro, M. G., Frogheri, L., Paliogiannis, P., Capobianco, G., Madonia, M., Cossu, A., et al. (2023) · Cancers · doi:10.3390/cancers15051356 · Cited by 58
Dutcher, J. P., Flippot, R., Fallah, J., & Escudier, B. J. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280817 · Cited by 61
Budczies, J., Kirchner, M., Kluck, K., Kazdal, D. N., Glade, J., Allgäuer, M., Kriegsmann, M., Heußel, C. P., Herth, F. J. F., Winter, H., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02981-w · Cited by 55
Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer
Fanale, D., Dimino, A., Pedone, E., Brando, C., Corsini, L. R., Filorizzo, C., Fiorino, A., Lisanti, M. C., Magrin, L., Randazzo, U., et al. (2022) · Cancers · doi:10.3390/cancers14184344 · Cited by 60
Koh, Y. W., Han, J.-H., Yoon, D. H., Suh, C., & Huh, J. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3115-6 · Cited by 48
“Previous study revealed that VEGF-A produced in the tumor microenvironment enhanced PD-1 expression on CD8+ T cells in mouse models of colon cancer [21].”
BackgroundResultReguera-Nuñez, E., Xu, P., Chow, A., Man, S., Hilberg, F., & Kerbel, R. S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0999-5 · Cited by 53
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
Ngiow, S. F., & Young, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01633 · Cited by 54
“By combining VEGF-targeted therapies and anti-PD-1, improved anti-tumor immune response was achieved (121, 122).”
BackgroundTherapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review
Puisieux, M. F., Pellat, A., Assaf, A., Ginestet, C., Brézault, C., Dhooge, M., Soyer, P. A., & Coriat, R. (2022) · Cancers · doi:10.3390/cancers14102357 · Cited by 55
Resistance to immune checkpoint inhibitors and the tumor microenvironment
Kawashima, S., & Togashi, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14716 · Cited by 55
The role of mitochondria in the resistance of melanoma to PD-1 inhibitors
Du, F., Yang, L.-H., Liu, J., Wang, J., Fan, L., Duangmano, S., Liu, H., Liu, M., Wang, J., Zhong, X., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04200-9 · Cited by 54
“Tregs in TME can reduce the content of IL-2 in TME and promote the expression of CTLA4 by producing immunosuppressive components such as TGF-β, IL-10 and extracellular adenosine, thus inhibiting the physiological function of CD8+ T cells and favouring immune evasion of melanoma cells [86].”
BackgroundBridging angiogenesis and immune evasion in the hypoxic tumor microenvironment
Schito, L. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00209.2018 · Cited by 52
Wu, F. T. H., Xu, P., Chow, A., Man, S., Krüger, J., Khan, K. A., Paez-Ribes, M., Pham, E., & Kerbel, R. S. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0297-1 · Cited by 47
What is the status of immunotherapy in thyroid neoplasms?
García‐Álvarez, A., Hernando, J., Carmona-Alonso, A., & Capdevila, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.929091 · Cited by 50
“Those receptors, upon activation in immune cells, can lead to T-cell exhaustion and Treg induction (64).”
BackgroundGuinn, S. R., Kinny‐Köster, B., Tandurella, J. A., Mitchell, J. T., Sidiropoulos, D. N., Loth, M., Lyman, M. R., Pucsek, A. B., Zabransky, D. J., Lee, J. W., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1660 · Cited by 51
Comparative haemato-immunotoxic impacts of long-term exposure to tartrazine and chlorophyll in rats
Abd‐Elhakim, Y. M., Hashem, M. M., El‐Metwally, A. E., Anwar, A., Abo‐EL‐Sooud, K., Moustafa, G. G., & Ali, H. A. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.002 · Cited by 55
An emerging role for cellular crosstalk in the cancer stem cell niche
Oshimori, N., Guo, Y., & Taniguchi, S. (2021) · The Journal of Pathology · doi:10.1002/path.5655 · Cited by 51
“Additionally, VEGF-A is known to induce the expression of programmed cell death protein 1 (PD-1) and other immune checkpoint molecules involved in CD8 T cell exhaustion, establishing an immunosuppressive microenvironment [40], which is a preferred feature of the CSC niche.”
BackgroundLee, D. Y., Im, E., Yoon, D., Lee, Y., Kim, G., Kim, D., & Kim, S.-H. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.001 · Cited by 52
Zheng, W., Qian, C., Tang, Y., Yang, C., Zhou, Y., Shen, P., Chen, W., Yu, S., Wei, Z., Wang, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035323 · Cited by 53
Difference in Immunosuppressive Cells Between Peritumoral Area and Tumor Core in Glioblastoma
Tamura, R., Ohara, K., Sasaki, H., Morimoto, Y., Kosugi, K., Yoshida, K., & Toda, M. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.08.133 · Cited by 52
Hypoxia: Turning vessels into vassals of cancer immunotolerance
Schito, L., & Rey, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.015 · Cited by 49
“an anti-VEGF neutralizing antibody, as shown in CT26 immunocompetent mouse tumors [135].”
BackgroundEmerging Immunotherapies in the Treatment of Brain Metastases
Nieblas‐Bedolla, E., Nayyar, N., Singh, M., Sullivan, R. J., & Brastianos, P. K. (2020) · The Oncologist · doi:10.1002/onco.13575 · Cited by 52
“Also, VEGF found in the tumor microenvironment enhances expression of inhibitory checkpoints, including PD-1, which can be reverted using antiangiogenic agents in animal models [35].”
BackgroundBao, R., Spranger, S., Hernandez, K. M., Zha, Y., Pytel, P., Luke, J. J., Gajewski, T. F., Volchenboum, S. L., Cohn, S. L., & Desai, A. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002417 · Cited by 49
Barroso‐Sousa, R., Keenan, T. E., Li, T., Tayob, N., Trippa, L., Pastorello, R., Richardson, E. T., Dillon, D. A. R., Amoozgar, Z., Overmoyer, B. A., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00287-9 · Cited by 49
More than a scaffold: Stromal modulation of tumor immunity
Johansson, A., Hamzah, J., & Ganß, R. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.001 · Cited by 49
“Moreover, VEGF blockade acts synergistically with anti PD-1 antibodies to improve anti-tumor immunity in mouse models [125].”
BackgroundTumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy
Li, S., Zhang, Q., & Hong, Y. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820980116 · Cited by 54
“VEGF binds to VEGFR2 on the surface of CD8þ T cells, resulting in upregulation of PD-1, CTLA-4, T cell immunoglobulin mucin receptor 3 (TIM3) and lymphocyte activation gene 3 (LAG3) protein expression, contributing to T cell exhaustion.(48,50) Second, VEGF can also hinder the maturation and antigen presentation of den…”
BackgroundPan, J.-B., Sheng, S., Ye, L., Xu, X., Ma, Y., Feng, X., Qiu, L., Fan, Z., Wang, Y., Xia, X., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00760-9 · Cited by 48
Anti-angiogenesis: Opening a new window for immunotherapy
Guo, F., & Cui, J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118163 · Cited by 49
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Haibe, Y., Husseini, Z. E., Sayed, R. E., & Shamseddine, A. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176176 · Cited by 47
“Moreover, it was found that VEGF induces immunosuppression through the downregulation of DCs, decreased activity and recruitment of CD8+ T-cells and stimulation of the expression of different checkpoints such as PD-1, TIM-3 and CTLA-4 on activated cytotoxic T-cells, leading to resistance to immune checkpoint inhibitor…”
BackgroundReversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations
Tabana, Y., Moon, T. C., Siraki, A. G., Elahi, S., & Barakat, K. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1937123 · Cited by 50
“VEGF-A also increases the co-expression of various coinhibitory receptors in T cells including CTLA-4, PD-1, and Tim3 [168].”
BackgroundHatanaka, T., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13748 · Cited by 48
“Another mechanism involves anti‐ VEGF agents inhibiting the expansion of immune‐suppressive myeloid‐derived suppressor cells, which promote an immunosuppressive microenvironment via the development of T‐regulatory cells.(23,24) These mechanisms support the clinical benefits of combination therapy with immune checkpoin…”
BackgroundTumor angiogenesis and anti-angiogenic therapy
Guo, Z., Xu, J., Sun, X., Sun, S., Yang, Y., & Cao, Y. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003231 · Cited by 55
“[116,117] VEGF-induced immunosuppressive effects include:”
Eptaminitaki, G. C., Wolff, N. S., Stellas, D., Sifakis, K., & Baritaki, S. (2021) · Cells · doi:10.3390/cells10123313 · Cited by 46
He, R., Lao, Y., Yu, W., Zhang, X., Jiang, M., & Zhu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.764618 · Cited by 48
Xiang, Y., Wang, K., Yu, H., Li, X., Cheng, Y., Wang, W., Feng, J.-K., Bo, M., Qin, Y., Zheng, Y., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13773 · Cited by 48
“Moreover, VEGF has been shown to regulate the checkpoint expression of T cells themselves in vitro and ex vivo.(38) Targeting antiangiogenic agents can increase the efficacy of ICIs and enhance antitumor immunity through various pathways.”
BackgroundBurgers, F. H., van der Mijn, J. C., Seijkens, T. T. P., Jedema, I., Bex, A., & Haanen, J. B. A. G. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00983-w · Cited by 60
Malo, C. S., Khadka, R. H., Ayasoufi, K., Jin, F., Chehade, J. E. A., Hansen, M. J., Iezzi, R., Pavelko, K. D., & Johnson, A. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00320 · Cited by 43
“CD8T cell exhaustion has been shown to be mediated by the immune suppressive tumor microenvironment, and VEGF is likely one way this is accomplished (14).”
BackgroundMethodInfluentialA Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy
Duru, G., van Egmond, M., & Heemskerk, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584723 · Cited by 48
“In addition,VEGFhasalsobeen implicated in inhibitionofTcell function by inducing increased expression of immune inhibitory checkpoints including PD-1, CTLA-4, and Tim-3mediating T cell exhaustion and anergy (9, 49).”
BackgroundInfluentialCousin, S., Guégan, J., Shitara, K., Palmieri, L., Guégan, J., Pernot, S., Fukuoka, S., Koyama, S., Nishikawa, H., Bellera, C. A., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02092-x · Cited by 42
Self-citationZakharia, Y., Bhattacharya, A., & Rustum, Y. M. (2018) · Oncotarget · doi:10.18632/oncotarget.24297 · Cited by 48
“An unstable TME is associated with an increased expression of PD-L1 in tumor cells [93].”
BackgroundChen, X., Zhang, W., Yang, W., Zhou, M., & Liu, F. (2022) · Aging · doi:10.18632/aging.203833 · Cited by 47
Fang, J., Hu, B., Li, S., Zhang, C., Liu, Y., & Wang, P. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.7 · Cited by 43
CAR-T cells and combination therapies: What’s next in the immunotherapy revolution?
Ramello, M. C., Haura, E. B., & Abate‐Daga, D. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.035 · Cited by 46
Molecular Targets in Hepatocarcinogenesis and Implications for Therapy
Wu, M., Yiang, G.-T., Cheng, P., Chu, P., & Li, C.-J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080213 · Cited by 45
Saigí, M., Alburquerque-Béjar, J. J., & Sánchez‐Céspedes, M. (2019) · Oncogene · doi:10.1038/s41388-019-0855-x · Cited by 41
Nano drug delivery system reconstruct tumour vasculature for the tumour vascular normalisation
Liang, Q., Zhou, L., Li, Y., Liu, J., & Liu, Y. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1927056 · Cited by 46
Feng, Y., Wu, J., Chen, J., Lın, L., Zhang, S., Yang, Z., Sun, P., Li, Y., Tian, H., & Chen, X. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101194 · Cited by 42
Johnson, R. L., Cummings, M., Thangavelu, A., Theophilou, G., Jong, D. D., & Orsi, N. M. (2021) · Cancers · doi:10.3390/cancers13246231 · Cited by 41
Telli, T. A., Bregni, G., Vanhooren, M., Saúde-Conde, R., Hendlisz, A., & Sclafani, F. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102460 · Cited by 46
Kheshtchin, N., & Hadjati, J. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30643 · Cited by 44
“directly induce PD1 and other inhibitory checkpoints on CTLs thereby, promoting T cell exhaustion (Voron et al., 2015).”
BackgroundSilaghi, H., Lozovanu, V., Georgescu, C. E., Pop, C., Năsui, B. A., Cătoi, A. F., & Silaghi, C. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073470 · Cited by 43
Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies
ter Linden, E., Abels, E. R., van Solinge, T. S., Neefjes, J., & Broekman, M. L. D. (2024) · Cells · doi:10.3390/cells13120998 · Cited by 53
“Furthermore, cytokines expressed by the CECs can create an immunosuppressive environment that hampers leucocyte activation and extravasation [49,50].”
BackgroundWu, X., Giobbie‐Hurder, A., Connolly, E. M., Li, J., Liao, X., Severgnini, M., Zhou, J. M., Rodig, S. J., & Hodi, F. S. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440930 · Cited by 42
Luo, L., Xiao, Y., Zhu, G., Huang, A., Song, S., Wang, T., Ge, X., Xie, J., Deng, W., Hu, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004652 · Cited by 42
“The underlying mechanism of the synergistic antitumor effect of the HAIC plus TKI and PD-1 might be as follows: 1) HAIC induces tumor antigen exposure through persistent highconcentration chemotherapeutic drug penetration, increases antigenicity through immunogenic cell death of tumor cells, and improves the tumor imm…”
BackgroundSunitinib in kidney cancer: 10 years of experience and development
Nassif, E. F., Thibault, C., Vano, Y. A., Fournier, L. S., Mauge, L., Verkarre, V., Timsit, M., Méjean, A., Tartour, É., & Oudard, S. M. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1272415 · Cited by 39
“Moreover, in murine models, sunitinib treatment decreases the expression of inhibitory receptors such as CTLA4 and PD-1 [78].”
BackgroundFibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma
Chiavarina, B., Ronca, R., Otaka, Y., Sutton, R. B., Rezzola, S., Yokobori, T., Chiodelli, P., Souche, F.-R., Pourquier, D., Maraver, A., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02171-z · Cited by 46
“The additional rationale of blocking VEGF lies in the ability of this growth factor to also suppress immunity and hence synergize with ICI to promote tumor progression [7].”
BackgroundChoi, S. H., Yoo, S. S., Lee, S. Y., & Park, J. Y. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01382-6 · Cited by 41
“In addition, VEGF inhibits the differentiation and proliferation of CD8 + CTLs and induces the upregulation of immune checkpoint molecules such as programmed death 1 (PD-1), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and T-cell immunoglobulin mucin receptor 3 (TIM-3), leading to CTL exhaustion (Voron et al.…”
BackgroundTargeting T-cell metabolism to boost immune checkpoint inhibitor therapy
Li, H., Zhao, A., Li, M., Shi, L., Han, Q., & Hou, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1046755 · Cited by 50
“In addition, high levels of transforming growth factor b (TGF-b) and the angiogenesis-promoting molecule VEGF-A regulate the expression of immune checkpoint molecules on CD8+T cells in the TME (39, 40).”
BackgroundImmune checkpoint inhibitors in the treatment of hepatocellular carcinoma
Akbulut, Z., Aru, B., Aydın, F., & Demirel, G. Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1379622 · Cited by 43
Bromley, J. D., Ganchua, S. K. C., Nyquist, S. K., Maiello, P. A., Chao, M. C., Borish, H. J., Rodgers, M., Tomko, J. A., Kracinovsky, K. B., Mugahid, D., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.002 · Cited by 44
Advances in Immunotherapy in Hepatocellular Carcinoma
Bloom, M., Podder, S., Dang, H. T., & Lin, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051936 · Cited by 42
“For example, VEGF-A has been shown to increase PD-1 expression on activated CD8+ T cells, which may be effectively blocked by anti-VEGF-A antibodies in vitro [60].”
Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism
Rosa, V. D., Rella, F. D., Giacomo, A. D., & Matarese, G. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.04.001 · Cited by 38
Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
Vokes, N. I., Pan, K., & Le, X. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231161409 · Cited by 45
Oncometabolites—A Link between Cancer Cells and Tumor Microenvironment
Baryła, M., Semeniuk-Wojtaś, A., Róg, L., Kraj, L., Małyszko, M., & Stec, R. (2022) · Biology · doi:10.3390/biology11020270 · Cited by 50
“Additionally, in animal and human models, VEGF has an inhibitory effect on the differentiation of progenitor cells into CD4+ and CD8+ cells [35,36] and increases the expression of PD‐L1, cytotoxic T‐cell antigen 4 (CTLA‐4), T‐cell immu‐ noglobulin and mucin domain 3 (TIM‐3), and lymphocyte activation gene 3 protein (L…”
BackgroundOzaki, Y., Tsurutani, J., Mukohara, T., Iwasa, T., Takahashi, M., Tanabe, Y., Kawabata, H., Masuda, N., Futamura, M., Minami, H., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.014 · Cited by 41
The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma
Ghosh, M., Lenkiewicz, A. M., & Kaminska, B. (2022) · Biomedicines · doi:10.3390/biomedicines10092292 · Cited by 42
“VEGF upregulates T cell immunoglobulin mucin receptor 3 (TIM3) and lymphocyte activation gene 3 (LAG3) protein expression, contributing to T cell exhaustion [58,63].”
BackgroundDesai, P. N., Wang, B., Fonseca, A., Borges, P., Jelloul, F. Z., Reville, P. K., Lee, E. J., Ly, C. P., Basi, A., Root, J. L., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0961 · Cited by 41
Fang, X., Zhu, N., Zhong, C., Wang, L., Li, J., Weng, S., Hu, H., Dong, C., Li, D., Song, Y., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102123 · Cited by 38
Immunotherapy in Ovarian Cancer
Wang, W., Liu, J. R., & Zou, W. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.002 · Cited by 43
Yeku, O., Rao, T. D., Laster, I., Kononenko, A. P., Purdon, T. J., Wang, P., Cui, Z., Liu, H., Brentjens, R. J., & Spriggs, D. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663379 · Cited by 39
“VEGF-A has been shown to directly upregulate PD-1 expression on T-cells and promote an “exhausted” immunophenotype (46).”
BackgroundControl of Tumor Progression by Angiocrine Factors
Alsina‐Sanchís, E., Mülfarth, R. I., & Fischer, A. (2021) · Cancers · doi:10.3390/cancers13112610 · Cited by 39
“Tumor ECs can secrete Inf-γ [45] and VEGF-A [71], which influence T cell responses.”
BackgroundTargeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Wang, C., & Fakih, M. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1933940 · Cited by 40
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
Li, Z., Sun, G., Sun, G., Cheng, Y., Wu, L., Wang, Q., Lv, C., Zhou, Y., Xia, Y., & Tang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771335 · Cited by 42
Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma
Jain, S., Chalif, E. J., & Aghi, M. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.812916 · Cited by 38
“VEGF enhances a number of inhibitory checkpoints involved in T cell exhaustion including PD1, as Tim-3, CTLA-4, and Lag-3 (104).”
Background
Metadata
- Authors
- Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., Stockmann, C., Combe, P., Berger, A., Zinzindohoue, F., Yagita, H., Tartour, E., Taieb, J., & Terme, M.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Service d’immunologie biologique 2 , 3 , 4 , 5
- Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan 6
- INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, Sorbonne Paris Cité, 75015 Paris, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-01-19
- Volume
- 212
- Issue
- 2
- Pages
- 139-148
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4322048
- OpenAlex
- W2156906256
- Cited by
- 1,179
- References
- 32
- Citations by year
- 2026: 81 · 2025: 100 · 2024: 121 · 2023: 142 · 2022: 169 · 2021: 147 · 2020: 127 · 2019: 92 · 2018: 81 · 2017: 51 · 2016: 50 · 2015: 16
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Ligue Contre le Cancer
- Assistance publique-Hôpitaux de Paris
- Fonds d’Etudes et de Recherche du Corps Médical
- Japan Society for the Promotion of Science (26290059)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- VEGF-A, PD-1, CTLA-4, TIM-3, CD8+ T cell exhaustion, tumor immune evasion, tumor microenvironment, anti-angiogenic therapy, VEGFR inhibition, immune checkpoint inhibitors, cancer immunotherapy
- MeSH terms
- Animals, Disease Models, Animal, Female, Neoplasms, Protein Binding, Signal Transduction, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Gene Expression Profiling, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Mice, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.